Direct effect of F12511, a systemic inhibitor of Acyl-CoA cholesterol acyltransferase on bovine aortic endothelial cells

Journal of Cardiovascular Pharmacology

Volumn 48, Issue 3, 2006, Pages 128-134

  Zamorano León, José J ^a   Fernández Sánchez, Ruth ^b   López Farré, Antonio J ^a   Lapuente Tiana, Lucía ^a   Alonso Orgaz, Sergio ^a   Sacristán, Daniel ^a   Junquera, Didier ^c   Delhon, André ^c   Conesa, Antonio ^c   Mateos Cáceres, Petra J ^a   Macaya, Carlos ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

CD40L; Endothelium; Inflammation; Nitric oxide; PECAM

Indexed keywords

CD31 ANTIGEN; CD40 LIGAND; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; EFLUCIMIBE; ISOPROTEIN; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; AORTA; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; COW; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACETANILIDES; ANILIDES; ANIMALS; AORTA; CATTLE; CD40 LIGAND; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; STEROL O-ACYLTRANSFERASE; SULFHYDRYL COMPOUNDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33749842336     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000246263.67515.6a     Document Type: Article

References (40)

1. Rudel LL, Lee RG, Cockman TL. Acyl coenzyme A: cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis. Curr Opin Lipidol. 2001;12:21-27.
2. Buhman KF, Accad M, Farese RV. Mammalian acyl-CoA: cholesterol acyltransferases. Biochem Biophys Acta. 2000;1529:142-154.
3. Anderson RA, Joyce C, Davis M, et al. Identification of a form of acyl-CoA: cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J Biol Chem. 1998;273:26747-26754.
4. Oelkers P, Behari A, Cromley D, et al. Characterization of two human genes encoding acyl coenzyme A: cholesterol acyltransferase-related enzymes. J Biol Chem. 1998;273:26765-26771.
5. Sliskovic DR, White AD. Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. Trends Pharmacol Sci. 1991;12:194-199.
6. Nicolosi RJ, Wilson TA, Krause BR. The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters. Atherosclerosis. 1998;137:77-85.
7. Kusunoki J, Hansoty DK, Aragane K, et al. Acyl-CoA: cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2001;103:2604-2609.
8. Suckling KE, Stange EF. Role of acyl-CoA: cholesterol acyltransferase in cellular cholesterol metabolism. J Lipid Res. 1985;26:647-671.
9. Jialal I, Chait A. Differences in the metabolism of oxidatively modified low density lipoprotein and acetylated low density lipoprotein by human endothelial cells: inhibition of cholesterol esterification by oxidatively modified low density lipoprotein. J Lipid Res. 1989;30:1561-1568.
10. Sakashita N, Miyazaki A, Takeya M, et al. Localization of human acyl-coenzyme A: cholesterol acyltransferase-1 (ACAT-1) in macrophages and in various tissues. Am J Pathol. 2000;156:227-236.
11. Roth BD. ACAT inhibitors: evolution from cholesterol-absorption inhibitors to antiatherosclerotic agents. Drug Discor Today. 1998;3:19-25.
12. Junquero D, Oms P, Carilla-Durand E, et al. Pharmacological profile of F 12511, (S)-2′,3′,5′-trimethyl-4′-hydroxy-alpha- dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor. Biochem Pharmacol. 2001;61:97-108.
13. Chang CC, Sakashita N, Ornvold K, et al. Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. J Biol Chem. 2000;275:28083-28092.
14. Rival Y, Junquero D, Bruniquel F, et al. Anti-atherosclerotic properties of the acyl-coenzyme A: cholesterol acyltransferase inhibitor F12511 in caseinfed New Zealand rabbits. J Cardiovas Pharmacol. 2002;39:181-191.
15. Anderson HD, Rahmutula D, Gardner DG. Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. J Biol Chem. 2004;279:963-969.
16. de Frutos T, Sanchez de Miguel L, Farre J, et al. Expression of an endothelial-type nitric oxide synthase isoform in human neutrophils: modification by tumor necrosis factor-alpha and during acute myocardial infarction. J Am Coll Cardiol. 2001;37:800-807.
17. Chua PK, Yanagihara R, Melish ME, et al. Modulation of adhesion molecules and monocyte chemoattractant protein by tumor necrosis factor-alpha and salicylic acid in primary human coronary artery endothelial cells. Cell Mol Biol. 2003;49:1157-1166.
18. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol. 2006;147(Suppl 1):S193-S201.
19. Lopez Farre A, Mosquera JR, Sanchez de Miguel L, et al. Endothelial cells inhibit NO generation by vascular smooth muscle cells. Role of transforming growth factor-beta. Arterioscler Thromb Vasc Biol. 1996;16:1263-1268.
20. Molero L, Farre J, Garcia-Mendez A, et al. Endothelin-1 induced proinflammatory markers in the myocardium and leukocytes of guinea-pigs: role of glycoprotein IIB/IIIA receptors. Cardiovasc Res. 2003;57:109-118.
21. Laemmli NV. Change of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
22. Marques M, Millas I, Jimenez A, et al. Alteration of the soluble guanylate cyclase system in the vascular wall of lead-induced hypertension in rats. J Am Soc Nephrol. 2001;12:2594-2600.
23. Yang L, Yang JB, Chen J, et al. Enhancement of human ACAT1 gene expression to promote the macrophage-derived foam cell formation by dexamethasone. Cell Res. 2004;14:315-323.
24. Smith JL, Rangaraj K, Simpson R, et al. Quantitative analysis of the expression of ACAT genes in human tissues by real-time PCR. J Lipid Res. 2004;45:686-696.
25. Matsukawa M, Fukuda K, Yoshida K, et al. Enhancement of nitric oxide and proteoglycan synthesis due to cyclic tensile strain loaded on Chondrocytes attached to fibronectin. Inflamm Res. 2004;53:239-244.
26. Sánchez de Miguel L, Arriero MM, Farré J, et al. Nitric oxide production by neutrophils obtained from patients during acute coronary syndromes: expression of the nitric oxide synthase isoforms. J Am Col Cardiol. 2002;39:818-825.
27. Neumann P, Gertzberg N, Johnson A. TNF-alpha induces a decrease in eNOS promoter activity. Am J Physiol. 2004;286:L452-L459.
28. MacNaul KL, Hutchinson NI. Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. Biochem Biophys Res Commun. 1996;196:1330-1334.
29. Matsuo M, Ito F, Konto A, et al. Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits. Evidence for a direct effect on the arterial wall. Biochim Biophys Acta. 1995;1259:254-260.
30. De Palma C, Meacci E, Pernotta C, et al. Endotelial nitric oxide synthase activation by tumor necrosis factor-a through neutral sphingomyelinase 2, sphingosine kinase 1 and Sphingosine 1 phosphate recectors. A novel pathway relevant to the pathophysiology of endothelium. Arterioscler Thromb Vasc Biol. 2006;26:99-105.
31. Monton M, Lopez-Farre A, Mosquera JR, et al. Endogenous angiotensin II produced by endothelium regulates interleukin-1beta-stimulated nitric oxide generation in rat isolated vessels. Hypertension. 1997;30:1191-1197.
32. Kubes P, Suzuk M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 1991;88:4651-4655.
33. Aukrustm P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100:614-620.
34. Schonbeck U, Varo N, Libby P, et al. P.M. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266-2268.
35. Soeki T, Tamura Y, Shinohara H, et al. Increased soluble platelet/endothelial cell adhesion molecule-1 in the early stages of acute coronary syndromes. Int J Cardiol. 2003;90:261-268.
36. Kuhlencordt PJ, Rosel E, Gerszten RE, et al. Role of endothelial nitric oxide synthase in endothelial activation: insights from eNOS knockout endothelial cells. Cell Physiol. 2004;286:C1195-C1202.
37. Fox PL, DiCorleto PE. Modified low density lipoproteins suppress production of a platelet-derived growth factor-like protein by cultured endothelial cells. Proc Natl Acad. Sci. USA. 1986;83:4774-4778.
38. Accad M, Smith SJ, Newland DL, et al. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl-CoA: cholesterol acyltransferase 1. J Clin Invest. 2000;105:711-719.
39. Willner EL, Tow B, Buhman KK, et al. Deficiency of acyl CoA: cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-defient mice. Proc Natl Acad Sci USA. 2003;100:1262-1267.
40. Miyazaki A, Sakashita N, Lee O, et al. expression of ACAT-1 protein in human atherosclerotic lesions and cultured human monocytes-macrophages. Arterioscler Thromb Vasc Biol. 1998;18:1568-1574.